Genmab A/S

Genmab A/S (GMAB) priced its initial public offering on Jul 19, 2019 at $17.75 per ADS, raising $505.9M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $1.14B. Morgan Stanley was lead-left underwriter, joined by Jefferies, Guggenheim and RBC Capital Markets and others. A&O Shearman advised the company and Latham & Watkins and Bech-Bruun Law Firm advised the underwriters.

Genmab A/S is an international biotechnology company specializing in antibody therapeutics for cancer and other diseases. Its portfolio includes partnered products daratumumab (marketed as DARZALEX for multiple myeloma) and ofatumumab (Arzerra for chronic lymphocytic leukemia), plus a pipeline of antibody candidates.

Status

IPO

Ticker

GMAB

Exchange

Nasdaq Global Select

Priced

Jul 19, 2019

IPO price

$17.75 per ADS

Raised

$505.9M

Market cap at IPO price

$1.14B

First filed

May 28, 2019

Underwriters

Morgan Stanley, Jefferies, Guggenheim, RBC Capital Markets and H.C. Wainwright

Company counsel

A&O Shearman

Underwriters' counsel

Latham & Watkins and Bech-Bruun Law Firm

Sector

Biotech & pharma

Country / state

Denmark

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.